Skip Navigation

JNCI Journal of the National Cancer Institute 2005 97(16):1178-1179; doi:10.1093/jnci/dji270
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Vastag, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Vastag, B.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2005 Oxford University Press

NEWS

Near-Final Word on Adjuvant Chemotherapy for Breast Cancer Is Good News

Brian Vastag

The first 10% of the full text of this article appears below.

The largest-ever compilation of trial data on early breast cancer has confirmed that adjuvant chemotherapy reduces death rates up to 15 years after disease onset. The meta-analysis also provides strong evidence in favor of tamoxifen treatment for women with hormone-responsive tumors.

The report, published earlier this summer in The Lancet by the European Breast Cancer Trialists' Collaborative Group (EBCTCG), shows that adjuvant chemotherapy provides "a very definitive alteration in the course of breast cancer. It's not just a temporary boost," said Gabriel . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?